Want to see USNA full AI Analyst Report?
USNA Stock Chart & Stats
$22.53
-$0.56(-1.60%)
At close: 4:00 PM EST
$22.53
-$0.56(-1.60%)
Day’s Range― - ―
52-Week Range$16.60 - $38.32
Previous CloseN/A
Volume19.92K
Average Volume (3M)173.43K
Market Cap
$413.57M
Enterprise Value$213.63
Total Cash (Recent Filing)$162.75M
Total Debt (Recent Filing)$14.00M
Price to Earnings (P/E)47.4
Beta1.10
Next Earnings
Aug 04, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding18,463,010
10 Day Avg. Volume170,208
30 Day Avg. Volume173,431
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.68
Price to Sales (P/S)0.39
P/FCF Ratio42.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.12
Revenue Forecast (FY)$938.74M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue RecoverySustained ~77% gross margin indicates durable product-level profitability and pricing power in supplements/personal care. Combined with returning TTM revenue growth, this supports long-term reinvestment in product development and channel expansion while cushioning operating margins from modest topline variability.
Conservative Balance Sheet With Very Low DebtExtremely low leverage provides structural financial flexibility to fund retail rollouts, inventory builds, and technology initiatives without heavy refinancing risk. This reduces vulnerability to rate cycles and gives management optionality to invest in omni-channel growth or weather macro shocks over the next several months.
Omni-channel Diversification; Rise & HYA MomentumRapid retail traction for Rise and accelerating HYA subscription growth represent structural diversification away from legacy distributor reliance. Target/Costco placements plus rising omni-channel mix (>20% guidance) enhance recurring revenue mix, broaden distribution, and reduce single-channel concentration risk over the medium term.
Bears Say
Compressed Profitability & Weak Free Cash FlowSharp margin compression and minimal free cash flow materially limit internal funding capacity for marketing, inventory and technology, and constrain shareholder returns. Persistently low cash generation raises sensitivity to execution hiccups and reduces cushion for multi-channel expansion over the coming quarters.
Elevated HYA Customer-acquisition Costs And Higher SG&ASustained higher CAC undermines HYA unit economics and delays path-to-profitability for the brand. If elevated marketing spend persists, SG&A pressure will continue to compress consolidated margins and require either slower growth or additional investment to achieve scale, impacting near-term earnings durability.
Cash Used To Build Retail Inventory; Cadence UncertaintyUpfront inventory financing for rapid retail rollouts strains liquidity and raises working-capital risk if reorder patterns are uneven. Uncertain retailer cadence (Costco variability) can amplify inventory risk, tying up cash and hampering flexibility to fund other strategic priorities over multiple quarters.
USANA Health News
USNA FAQ
What was USANA Health’s price range in the past 12 months?
USANA Health lowest stock price was $16.60 and its highest was $38.32 in the past 12 months.
What is USANA Health’s market cap?
USANA Health’s market cap is $413.57M.
When is USANA Health’s upcoming earnings report date?
USANA Health’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were USANA Health’s earnings last quarter?
USANA Health released its earnings results on May 05, 2026. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17.
Is USANA Health overvalued?
According to Wall Street analysts USANA Health’s price is currently Overvalued.
Does USANA Health pay dividends?
USANA Health does not currently pay dividends.
What is USANA Health’s EPS estimate?
USANA Health’s EPS estimate is 0.43.
How many shares outstanding does USANA Health have?
USANA Health has 18,463,010 shares outstanding.
What happened to USANA Health’s price movement after its last earnings report?
USANA Health reported an EPS of $0.61 in its last earnings report, beating expectations of $0.44. Following the earnings report the stock price went up 3.894%.
Which hedge fund is a major shareholder of USANA Health?
Currently, no hedge funds are holding shares in USNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
USANA Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
USNA Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 32.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $619.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.02%
Trailing 12-Months
Company Description
USANA Health
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Technical Analysis
Ownership Overview
40.82% Insiders
10.58% Mutual Funds
0.24% Other Institutional Investors
37.12% Public Companies and
Individual Investors